Kim N.

机构：BC Cancer Agency, University of British Columbia, Asian Institute of Technology, BC Cancer Foundation · ORCID：0000-0002-3782-7226

发表论文 860 篇 · 总被引 52904 次 · h-index 83

代表论文

• Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 (2026 · Journal of Clinical Oncology · 被引 30)
• Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304) (2026 · European Urology Oncology · 被引 3)
• Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer (2025 · Nature Communications · 被引 2)
• Canadian Cancer Trials Group (CCTG) study PR21 (PLUDO): Results of crossover treatment from a randomized trial of 177 Lu-PSMA-617 (LuP) vs docetaxel (DOC) in patients with metastatic castration-resistant prostate cancer (mCRPC). (2026 · Journal of Clinical Oncology · 被引 1)
• Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01 (2026 · Future Oncology · 被引 1)
• Niraparib With Abiraterone Acetate Plus Prednisone as First‐Line Therapy in Patients With Metastatic Castration‐Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study (2026 · International Journal of Urology · 被引 1)